AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

AstraZeneca PLCNYSE: AZN

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) dips below year-ago levels

Q3 FY2026 weighted avg shares (diluted) of 1.56B shares fell 0.1% year over year, in line with the +0.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -0.1% toward the trailing-twelve-month pace of +0.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
1.56B+0.0% QoQ
Last fiscal yearDec 2025
1.56B-0.1% YoY
LTMSep 2026
1.56B+0.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.1%——
1 year-0.1%——
3-year CAGR+0.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
1.56B USD
Year-over-year change
-0.1%
4-year CAGR
+2.3%

Weighted Avg Shares (Diluted) vs competitors

How AZN compares with its peers on the latest reported figures

  • AZN's LTM Sep 2026 weighted avg shares (diluted) of 1.56B shares is the 8th highest of the 10 companies compared; the peer median is 2.04B shares.
  • Its year-over-year change of +0.0% is the 6th highest of 10, against a peer median of +0.0%.
  • Over three fiscal years its annual growth of +0.0% compares with a peer median of -0.7%.
AZN Competitors Peer median
Weighted Avg Shares (Diluted) for AZN and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.71B +0.0%-0.3%
NVONovo Nordisk A/SLTM Jun 20264.44B -0.2%-0.7%
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
JNJJohnson & JohnsonLTM Sep 20262.44B +0.8%-3.0%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.3%-1.7%
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.0%-0.1%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
LLYEli Lilly and CompanyLTM Jun 2026896.6M -0.6%-1.9%
AMGNAmgen Inc.LTM Jun 2026543.25M +0.3%+0.1%
Peer median (excluding AZN) 2.04B+0.0%-0.7%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.